Drug Trial Radar · NCT03611556
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
Last checked: Nov 19, 2026Latest source record: Oct 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
Jun 21, 2018
Primary completion
Jul 22, 2022
Study completion Jul 22, 2022
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 101 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
Conditions
- Carcinoma
- Metastatic Pancreatic Adenocarcinoma
Interventions
OleclumabDrug
Participants will receive IV infusion of oleclumab as stated in arm description.
DurvalumabDrug
Participants will receive IV infusion of durvalumab as stated in arm description.
GemcitabineDrug
Participants will receive IV infusion of gemcitabine as stated in arm description.
Nab-paclitaxelDrug
Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
OxaliplatinDrug
Participants will receive IV infusion of oxaliplatin as stated in arm description.
Folinic acidDrug
Participants will receive IV infusion of folinic acid as stated in arm description.
5-FUDrug
Participants will receive IV infusion of 5-FU as stated in arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
- Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation PhaseTime frame: From Day 1 to 28 days after the first dose of study drugs
- Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
- Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
- Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation PhaseTime frame: Day 1 through 65.7 weeks (maximum observed duration)
- Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion PhaseTime frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Locations
27 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Aurora, Colorado
Research Site
Fort Myers, Florida
Research Site
Atlanta, Georgia
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Buffalo, New York
Research Site
Durham, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Philadelphia, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Charlottesville, Virginia
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Blacktown, Australia
Research Site
Clayton, Australia
Research Site
Heidelberg, Australia
Research Site
St Leonards, Australia
Research Site
Oslo, Norway
Research Site
Barcelona, Spain
Research Site
Fuenlabrada, Spain
Research Site
Oviedo, Spain
Research Site
Pamplona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.